Press Release

3
Jun

Ichor Open House July 11th, 2015 11:00 AM – 3:00 PM

LaFayette, NY: Ichor Therapeutics, Inc., a pre-clinical biotechnology company that develops technologies to target age-related pathology, has announced a community open house on July 11th, 2015, from 11:00 AM – 3:00 PM. The company relocated to its new site in November, 2014, and has been renovating the facility to support life science research, including a 625 sq ft clean room.

Read more

1
Feb

CenterState CEO seeds Ichor macular degeneration program with Grants for Growth

LaFayette, NY: Ichor Therapeutics, Inc., a pre-clinical biotechnology company that develops technologies to target age-related pathology, has received a $25,000 grant from CenterState CEO through its Grants for Growth program. Announced in CenterState CEO’s February 2015 Newsletter, this funding will be used to develop an enzyme augmentation therapy to treat age-related macular degeneration, the leading cause of blindness and vision

Read more

14
Sep

Ichor meets $18,000 crowd-funding goal in just 7 days

Syracuse, NY: Ichor Therapeutics, Inc., a pre-clinical biotechnology company that develops technologies to target age-related pathology, announced today that its first crowd-funding campaign has met its $18,000 goal in only 7 days. These funds will be used to study the effects of c60, a potent antioxidant, on human cancer proliferation. Longecity.org and a private donor pledged two dollars in additional

Read more

9
Sep

Ichor Therapeutics, Inc. launches online store

Syracuse, NY: Today, Ichor Therapeutics. Inc, a pre-clinical biotechnology company that develops technologies to target age-related pathology, announced the formation of WeCellStuff.com. The store features numerous research products and also provides local researchers with affordable access to capital assets, such as liquid handling robots and a flow cytometer, among others. Ichor CEO Kelsey Moody stated, “The use of core infrastructure

Read more

2
Sep

Ichor crowd-funding initiative to receive matching contributions

Syracuse, NY: Ichor Therapeutics, Inc., a pre-clinical biotechnology company that develops technologies to target age-related pathology, announced today the initiation of its first crowd-funding campaign. The company aims to raise at least $19,500 to study the effects of c60, a potent antioxidant, on human cancer proliferation. Longecity.org and a private donor have pledged two dollars in additional contributions for every

Read more

1
Aug

Ichor Therapeutics, Inc. raises $383,000 for contract research from BioSenex, Ltd.

Syracuse, NY: Ichor Therapeutics, Inc., a pre-clinical biotechnology company that develops technologies to target age-related pathology, announced today that it has raised $383,000 for contract research from BioSenex, Ltd. BioSenex is a new venture that aims to develop supplement-based formulations to treat chronic disease. BioSenex will also enter as a contender for the Rejuvenation Mprize, a multi-million dollar competition to

Read more